News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
109–116
Matches
116
Sources here
8
Companies here
1
Search results Stored financial headlines

Active search

116 matching headlines

Ticker or company: DXCMMain company stories
Clear

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

Quiver Quantitative Analyst action Main company 🇺🇸 United States

Why DexCom (DXCM) Stock Is Up Today

DexCom (DXCM) stock rose by 7.2% today, primarily driven by a favorable analyst rating from Truist, which raised its price target to $87, citing improved growth visibility and potential margin upside. Additional support came from the recent Health Canada authorization for the G7 15 …

DXCM main company
Sharemaestro market context Trend signal active 52 weeks +9.1% DXCM stored weekly price path from 22 Aug 2025 to 14 Aug 2026
MarketWatch Market update Main company 🇺🇸 United States

DexCom Inc. stock underperforms Thursday when compared to competitors despite daily gains

DexCom Inc. (DXCM) shares rose 7.22% to $77.98 on Thursday, despite an overall tough trading day for the stock market where the S&P 500 and Dow Jones Industrial Average both fell. The gain ended a two-day losing streak for DexCom, although the article title …

DXCM main company
Sharemaestro market context Trend signal active 52 weeks +9.1% DXCM stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Investing.com Earnings Main company 🇺🇸 United States

Truist raises DexCom stock price target to $87 on growth outlook

Truist Securities has raised its price target for DexCom Inc. (NASDAQ:DXCM) to $87 from $80, maintaining a Buy rating due to the medical device company's attractive valuation, growth prospects, and potential catalysts. The firm highlights DexCom's strong gross profit margin of 61.5%, 16% revenue …

DXCM main company
Sharemaestro market context Trend signal active 52 weeks +9.1% DXCM stored weekly price path from 22 Aug 2025 to 14 Aug 2026
www.marketscreener.com Analyst action Main company 🇺🇸 United States

Truist Adjusts Price Target on DexCom to $87 From $80, Maintains Buy Rating

Truist has increased its price target for DexCom (DXCM) to $87 from $80, while reaffirming its "Buy" rating on the stock. This adjustment reflects an updated outlook from the analyst firm regarding the medical equipment company. The news was reported on July 16, 2026.

DXCM main company
Sharemaestro market context Trend signal active 52 weeks +9.1% DXCM stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Simply Wall Street Regulatory and legal Main company 🇺🇸 United States

How Health Canada’s Longer-Wear CGM Approval At DexCom (DXCM) Has Changed Its Investment Story

Health Canada recently approved DexCom's G7 15 Day Continuous Glucose Monitoring System, extending sensor wear to 15.5 days with high accuracy. This approval is expected to reinforce DexCom's market position in Canada by enhancing convenience and digital health integration, though investors are also urged …

DXCM main company
Sharemaestro market context Trend signal active 52 weeks +9.1% DXCM stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Market update Main company 🇺🇸 United States

DXCM Company (NASDAQ: DXCM) shareholder to sell 1,700 shares

Michael Brown plans to sell 1,700 shares of DXCM common stock through Morgan Stanley Smith Barney LLC Executive Financial Services around July 15, 2026, valued at $126,514.00. This planned sale follows two previous sales by Brown of 1,700 shares each in May and June …

DXCM main company
Sharemaestro market context Trend signal active 52 weeks +9.1% DXCM stored weekly price path from 22 Aug 2025 to 14 Aug 2026
marketscreener.com Analyst action Main company 🇺🇸 United States

Mizuho Adjusts Price Target on DexCom to $90 From $85, Maintains Outperform Rating

Mizuho analysts have increased their price target for DexCom (DXCM) to $90 from $85, while reiterating an Outperform rating on the stock. This adjustment reflects continued confidence in the medical equipment company, which specializes in continuous glucose monitoring systems. The article notes the price …

DXCM main company
Sharemaestro market context Trend signal active 52 weeks +9.1% DXCM stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Market source Earnings Main company 🇺🇸 United States

DXCM Secures Health Canada Authorization for Dexcom G7 15 Day CGM

DexCom (DXCM) has received Health Canada authorization for its Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System for adults with diabetes. This authorization marks a significant regulatory milestone, expanding access to DexCom's latest diabetes management technology in Canada. The Dexcom G7 15 Day …

DXCM main company
Sharemaestro market context Trend signal active 52 weeks +9.1% DXCM stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context